73 related articles for article (PubMed ID: 645407)
1. Metabolic fate of bromperidol in humans: comparison with rats and dogs.
Chasseaud LF
Acta Psychiatr Belg; 1978; 78(1):51-63. PubMed ID: 645407
[TBL] [Abstract][Full Text] [Related]
2. Biotransformation of bromperidol in rat, dog, and man.
Wong FA; Bateman CP; Shaw CJ; Patrick JE
Drug Metab Dispos; 1983; 11(4):301-7. PubMed ID: 6137334
[TBL] [Abstract][Full Text] [Related]
3. Absorption, distribution and excretion of [carbonyl-14C]mosapride citrate after a single oral administration in rats, dogs and monkeys.
Matsumoto S; Tagawa M; Amejima H; Nakao M; Kagemoto A; Fujii T; Miyazaki H; Sekine Y
Arzneimittelforschung; 1993 Oct; 43(10):1084-94. PubMed ID: 8267675
[TBL] [Abstract][Full Text] [Related]
4. Antilipidemic drugs. Part 4: The metabolic fate of the hypolipidemic agent isopropyl-[4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl]-protionate (LF 178) in rats, dog and man.
Brodie RR; Chasseaud LF; Elson FF; Franklin ER; Taylor T
Arzneimittelforschung; 1976; 26(5):896-901. PubMed ID: 989365
[TBL] [Abstract][Full Text] [Related]
5. Metabolism of labetalol by animals and man.
Martin LE; Hopkins R; Bland R
Br J Clin Pharmacol; 1976 Aug; 3(4 Suppl 3):695-710. PubMed ID: 990152
[TBL] [Abstract][Full Text] [Related]
6. Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.
Yamaguchi T; Nakajima Y; Mizobuchi M; Inazawa K; Kanazu T; Kadono K; Ohkawa T; Iwatani K
Arzneimittelforschung; 1998 Oct; 48(10):995-1006. PubMed ID: 9825117
[TBL] [Abstract][Full Text] [Related]
7. Absorption, distribution, metabolism and excretion of [14C]ebastine after a single administration in rats.
Fujii T; Matsumoto S; Amejima H; Hatoyama T; Nakao M; Kagemoto A; Tanaka K; Miyazaki H
Arzneimittelforschung; 1994 Apr; 44(4):527-38. PubMed ID: 7912071
[TBL] [Abstract][Full Text] [Related]
8. Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.
Zhang D; Wang L; Raghavan N; Zhang H; Li W; Cheng PT; Yao M; Zhang L; Zhu M; Bonacorsi S; Yeola S; Mitroka J; Hariharan N; Hosagrahara V; Chandrasena G; Shyu WC; Humphreys WG
Drug Metab Dispos; 2007 Jan; 35(1):150-67. PubMed ID: 17062777
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, protein binding and metabolic profile of 3H-icometasone enbutate following intravenous, oral and intratracheal administrations to Sprague-Dawley rats.
Duchêne P; Giudicelli MD; Neau B; Gronfier A; Firmin Y; Villax P; Saivin S; Houin G
Arzneimittelforschung; 1998 Apr; 48(4):371-8. PubMed ID: 9608879
[TBL] [Abstract][Full Text] [Related]
10. Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs.
Kobayashi S; Sakai T; Dalrymple PD; Wood SG; Chasseaud LF
Arzneimittelforschung; 1993 Dec; 43(12):1367-77. PubMed ID: 8141830
[TBL] [Abstract][Full Text] [Related]
11. The pharmacokinetics of nitrendipine. I. Absorption, plasma concentrations, and excretion after single administration of [14C]nitrendipine to rats and dogs.
Krause HP; Ahr HJ; Beermann D; Siefert HM; Suwelack D; Weber H
Arzneimittelforschung; 1988 Nov; 38(11):1593-9. PubMed ID: 3214442
[TBL] [Abstract][Full Text] [Related]
12. Excretion and metabolism of intramuscularly administered [14C]-haloperidol decanoate in rats.
Matsunaga Y; Nambu K; Oh-e Y; Miyazaki H; Hashimoto M
Arzneimittelforschung; 1986 Mar; 36(3):453-6. PubMed ID: 3707664
[TBL] [Abstract][Full Text] [Related]
13. Disposition of the opioid antagonist, LY255582, in rats and dogs.
Swanson SP; Catlow J; Pohland RC; Chay SH; Johnson T
Drug Metab Dispos; 1995 Sep; 23(9):916-21. PubMed ID: 8565781
[TBL] [Abstract][Full Text] [Related]
14. Metabolic fate of the new angiotensin-converting enzyme inhibitor imidapril in animals. 6th communication: interspecies comparison of pharmacokinetics and excretion of imidapril metabolites in rats, dogs, and monkeys.
Yamada Y; Endo M; Kohno M; Otsuka M; Takaiti O
Arzneimittelforschung; 1992 Apr; 42(4):499-506. PubMed ID: 1642673
[TBL] [Abstract][Full Text] [Related]
15. Distribution and excretion of (3H)vincristine in the rat and the dog.
Castle MC; Margileth DA; Oliverio VT
Cancer Res; 1976 Oct; 36(10):3684-9. PubMed ID: 953993
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and disposition of L-692,429. A novel nonpeptidyl growth hormone secretagogue in preclinical species.
Leung KH; Cohn DA; Miller RR; Doss GA; Stearns RA; Simpson RE; Feeney WP; Chiu SH
Drug Metab Dispos; 1996 Jul; 24(7):753-60. PubMed ID: 8818572
[TBL] [Abstract][Full Text] [Related]
17. Disposition of remoxipride in different species. Species differences in metabolism.
Widman M; Nilsson LB; Bryske B; Lundström J
Arzneimittelforschung; 1993 Mar; 43(3):287-97. PubMed ID: 8489555
[TBL] [Abstract][Full Text] [Related]
18. Studies on the metabolism and disposition of the new retinoid 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)carbamoyl] benzoic acid. 4th communication: absorption, metabolism, excretion and plasma protein binding in various animals and man.
Mizojiri K; Okabe H; Sugeno K; Misaki A; Ito M; Kominami G; Esumi Y; Takaichi M; Harada T; Seki H; Inaba A
Arzneimittelforschung; 1997 Mar; 47(3):259-69. PubMed ID: 9105544
[TBL] [Abstract][Full Text] [Related]
19. Excretion and biotransformation of cisapride in dogs and humans after oral administration.
Meuldermans W; Van Peer A; Hendrickx J; Lauwers W; Swysen E; Bockx M; Woestenborghs R; Heykants J
Drug Metab Dispos; 1988; 16(3):403-9. PubMed ID: 2900732
[TBL] [Abstract][Full Text] [Related]
20. Metabolic fate of the new Ca++-channel blocking agent (+)-(2S,3S)-3-acetoxy-8-chloro-(2-(dimethylamino)ethyl)-2,3-dihydro- 2-(4-methoxyphenyl)-2,5-benzothiazepin-4-(5H)-one maleate. Distribution, excretion and protein binding in rats and dogs.
Nakamura S; Ohashi M; Suzuki T; Sugawara Y; Usuki S; Takaiti O
Arzneimittelforschung; 1989 Sep; 39(9):1100-8. PubMed ID: 2590259
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
